Thursday , July 7 2022

transplanted IPS stem cells in the brain of a patient in Japan



[ad_1]

This is the first world that gives hope to people with Parkinson's disease. On Friday, November 9, researchers at the University of Kyoto, Japan, said in a statement that they successfully transplanted 2.4 million iPS stem cells in the left brain of a patient with Parkinson's disease. "induced pluripotent stem cells" or, in France, induced pluripotent cells).

The operation that took place last month lasted for three hours, says the medical team. A patient, a man in the fifties, was well tolerated. It will now be under surveillance for two years. If there is no problem within six months, doctors will implant another 2.4 million extra stem cells, this time on the right side of the patient's brain.

Pluripotent stem cells

Another common neurodegenerative disease of the nervous system after Alzheimer's disease, Parkinson's disease affects about 200,000 people in France and more than one million in Europe: in France, there are 8,000 new cases each year. According to the US Parkinson's Foundation, there are 10 million Parkinson's in the world.

Characterized by the progressive loss of neurons in the gray core of the brain, Parkinson's disease causes a gradual loss of movement control and the appearance of other motor symptoms such as tremor and stiffness of the extremities. Currently available treatments "improve symptoms, but without slowing progression of the disease," says the Foundation for Parkinson's Disease.

This new treatment with iPS stem cells from healthy donors offers new hope to patients. In fact, others have the distinction of being pluripotent: if they are transplanted into the brain, they are able to develop neurons that produce dopamine, a neurotransmitter involved in the control of motor skills.

A clinical trial of seven patients was announced

This successful essay by Japanese scientists is unlikely to be the last. Last July, the Kyoto University announced that a clinical trial of seven participants aged 50 to 69 would be launched. "I welcome patients because of their courage and decisive participation," said Professor Takahashi, quoted by NHK Public Television on Friday.

This clinical trial was based on an experiment that was performed on mother-hammock mothers, and is reported in an article in the Nature magazine in August 2017. According to the study, this transplant improved the capacity to receive with the shape of Parkinson's movements. The survival of cell transplanted cells by injection into the primate brain was observed for two years without any tumor appearance.

Are you interested in this topic? Come to discuss our forum!

[ad_2]
Source link